The Normal Range of Baseline Tryptase Should Be 1 to 15 ng/mL and Covers Healthy Individuals With HαT.

Hereditary alpha tryptasemia Mast cell activation syndromes Mastocytosis Tryptase

Journal

The journal of allergy and clinical immunology. In practice
ISSN: 2213-2201
Titre abrégé: J Allergy Clin Immunol Pract
Pays: United States
ID NLM: 101597220

Informations de publication

Date de publication:
10 2023
Historique:
received: 03 05 2023
revised: 27 07 2023
accepted: 01 08 2023
medline: 9 10 2023
pubmed: 13 8 2023
entrez: 12 8 2023
Statut: ppublish

Résumé

Physiological levels of basal serum tryptase vary among healthy individuals, depending on the numbers of mast cells, basal secretion rate, copy numbers of the TPSAB1 gene encoding alpha tryptase, and renal function. Recently, there has been a growing debate about the normal range of tryptase because individuals with the hereditary alpha tryptasemia (HαT) trait may or may not be symptomatic, and if symptomatic, uncertainty exists as to whether this trait directly causes clinical phenotypes or aggravates certain conditions. In fact, most HαT-positive cases are regarded as asymptomatic concerning mast cell activation. To address this point, experts of the European Competence Network on Mastocytosis (ECNM) and the American Initiative in Mast Cell Diseases met at the 2022 Annual ECNM meeting and discussed the physiological tryptase range. Based on this discussion, our faculty concluded that the normal serum tryptase range should be defined in asymptomatic controls, inclusive of individuals with HαT, and based on 2 SDs covering the 95% confidence interval. By applying this definition in a literature screen, the normal basal tryptase in asymptomatic controls (HαT-positive persons included) ranges between 1 and 15 ng/mL. This definition should avoid overinterpretation, unnecessary referrals, and unnecessary anxiety or anticipatory fear of illness in healthy individuals.

Identifiants

pubmed: 37572755
pii: S2213-2198(23)00907-8
doi: 10.1016/j.jaip.2023.08.008
pii:
doi:

Substances chimiques

Tryptases EC 3.4.21.59

Types de publication

Journal Article Review Research Support, N.I.H., Intramural Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

3010-3020

Subventions

Organisme : NIAID NIH HHS
ID : U19 AI104209
Pays : United States
Organisme : NIAID NIH HHS
ID : R01 AI165373
Pays : United States

Informations de copyright

Copyright © 2023 The Authors. Published by Elsevier Inc. All rights reserved.

Auteurs

Peter Valent (P)

Division of Haematology, Department of Internal Medicine I, Medical University of Vienna, Vienna, Austria; Ludwig Boltzmann Institute for Hematology and Oncology, Medical University of Vienna, Vienna, Austria. Electronic address: peter.valent@meduniwien.ac.at.

Gregor Hoermann (G)

Ludwig Boltzmann Institute for Hematology and Oncology, Medical University of Vienna, Vienna, Austria; MLL Munich Leukemia Laboratory, Munich, Germany.

Patrizia Bonadonna (P)

Allergy Unit, Verona University Hospital, Verona, Italy.

Karin Hartmann (K)

Division of Allergy, Department of Dermatology, University Hospital Basel and University of Basel, Basel, Switzerland; Department of Biomedicine, University Hospital Basel and University of Basel, Basel, Switzerland.

Wolfgang R Sperr (WR)

Division of Haematology, Department of Internal Medicine I, Medical University of Vienna, Vienna, Austria; Ludwig Boltzmann Institute for Hematology and Oncology, Medical University of Vienna, Vienna, Austria.

Sigurd Broesby-Olsen (S)

Department of Dermatology and Allergy Centre, Odense University Hospital, Odense, Denmark.

Knut Brockow (K)

Department of Dermatology and Allergy Biederstein, Technical University of Munich, Munich, Germany.

Marek Niedoszytko (M)

Department of Allergology, Medical University of Gdansk, Gdansk, Poland.

Olivier Hermine (O)

Service d'hématologie, Imagine Institute Université de Paris, Centre national de référence des mastocytoses, Hôpital Necker, Assistance publique hôpitaux de Paris, Paris, France.

Yannick Chantran (Y)

Department of Biological Immunology, Saint-Antoine Hospital, Paris Sorbonne University, Paris, France.

Joseph H Butterfield (JH)

Division of Allergic Diseases, Mayo Clinic, Rochester, Minn.

Georg Greiner (G)

Ludwig Boltzmann Institute for Hematology and Oncology, Medical University of Vienna, Vienna, Austria; Ihr Labor, Medical Diagnostic Laboratories, Vienna, Austria.

Melody C Carter (MC)

Laboratory of Allergic Diseases, National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH), Bethesda, Md.

Vito Sabato (V)

Faculty of Medicine and Health Sciences, Department of Immunology-Allergology-Rheumatology, University of Antwerp and Antwerp University Hospital, Antwerp, Belgium.

Deepti H Radia (DH)

Guy's & St. Thomas' National Health Service (NHS) Foundation Trust, Guy's Hospital, London, UK.

Frank Siebenhaar (F)

Institute of Allergology, Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Berlin, Germany; Fraunhofer Institute for Translational Medicine and Pharmacology (ITMP), Immunology and Allergology (IA), Berlin, Germany.

Massimo Triggiani (M)

Division of Allergy and Clinical Immunology, University of Salerno, Salerno, Italy.

Theo Gülen (T)

Department of Respiratory Medicine and Allergy, Karolinska University Hospital Huddinge, Stockholm, Sweden; Department of Medicine Solna, Division of Immunology and Allergy, Karolinska Institutet, Stockholm, Sweden.

Ivan Alvarez-Twose (I)

Instituto de Estudios de Mastocitosis de Castilla La Mancha (CLMast) and CIBERONC, Hospital Virgen del Valle, Toledo, Spain.

Thomas Staudinger (T)

Department of Internal Medicine I, Intensive Care Unit, Medical University of Vienna, Vienna, Austria.

Ludwig Traby (L)

Department of Internal Medicine I, Division of Infectious Diseases and Tropical Medicine, Medical University of Vienna, Vienna, Austria.

Karl Sotlar (K)

Institute of Pathology, University Hospital Salzburg, Paracelsus Medical University, Salzburg, Austria.

Andreas Reiter (A)

Department of Hematology and Oncology, University Hospital Mannheim, Mannheim, Germany.

Hans-Peter Horny (HP)

Institute of Pathology, Ludwig-Maximilians-University, Munich, Germany.

Alberto Orfao (A)

Servicio Central de Citometria, Centro de Investigacion del Cancer (IBMCC CSIC/USAL) Instituto Biosanitario de Salamanca (IBSAL), CIBERONC and Department of Medicine, University of Salamanca, Salamanca, Spain.

Stephen J Galli (SJ)

Department of Pathology, Department of Microbiology and Immunology, Sean N. Parker Center for Allergy and Asthma Research, Stanford University School of Medicine, Stanford, Calif.

Lawrence B Schwartz (LB)

Department of Internal Medicine, Division of Rheumatology, Allergy, and Immunology, Virginia Commonwealth University, Richmond, Va.

Jonathan J Lyons (JJ)

Translational Allergic Immunopathology Unit, Laboratory of Allergic Diseases, NIAID, NIH, Bethesda, Md.

Jason Gotlib (J)

Stanford University School of Medicine/Stanford Cancer Institute, Stanford, Calif.

Dean D Metcalfe (DD)

Laboratory of Allergic Diseases, National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH), Bethesda, Md.

Michel Arock (M)

Department of Hematological Biology, Pitié-Salpêtrière Hospital, Paris Sorbonne University, Paris, France.

Cem Akin (C)

Division of Allergy and Clinical Immunology, University of Michigan, Ann Arbor, Mich.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH